botanix
PHARMACEUTICALS
ACN 009 109 755

**ASX/Media Release**

**9 August 2019**

# Completion of Placement

## Key highlights

- **Botanix has issued the remaining 8.5m shares at an issue price of A$0.21 per share being A$1.8m to complete the A$40m Placement**

**Philadelphia PA and Sydney Australia, 9 August 2019:** Further to the ASX announcement on 7 August 2019, clinical stage cannabinoid company Botanix Pharmaceuticals Limited (ASX:BOT, "Botanix" or the "Company") is pleased to announce that it has today issued the 8,500,000 shares following the receipt of cleared funds to complete the A$40m placement announced on 1 August 2019 (**"Placement"**).

The funds from the Placement will enable Botanix to continue to execute its key clinical development programmes and accelerate its broader commercialisation strategy. Botanix is now fully funded to progress its first antimicrobial program into clinical studies and undertake supportive studies required prior to Phase 3 studies. Funds from the Placement are also available for general working capital use.

The shares were issued pursuant to the Company's Listing Rule 7.1 capacity. Following the issue, the total number of shares on issue is 964,504,395.

An Appendix 3B applying for quotation of the shares together with a cleansing notice in respect of the Placement shares pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) has been lodged with ASX.

**About Botanix Pharmaceuticals**

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company's focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions, together with a development platform of antimicrobial drug candidates. The active ingredient contained in Botanix products is a synthetic form of cannabidiol. Treatment targets for skin diseases include inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis. Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with patient treatment expected to complete in 3Q CY2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with enrolment expected to complete in 4Q CY2019. A mechanism of action study for Phase 1b BTX 1308 (psoriasis) has recently completed, with positive interim data announced in June 2019. Development of a pipeline of product candidates that leverages the antimicrobial properties of cannabidiol are also moving forward and first products are planned to enter the clinic in 2H CY2019.

To learn more please visit: https://www.botanixpharma.com/

**For more information, please contact:**


| **General enquiries** | **Investor enquiries** | **Media enquiries** |
|---|---|---|
| Corporate Communications | Joel Seah | Haley Chartres |
| Botanix Pharmaceuticals | Vesparum Capital | Hales$^2$ Communications |
| P: +61 8 6555 2945 | P: +61 3 8582 4800 | P: +61 423 139 163 |
| investors@botanixpharma.com | botanixpharma@vesparum.com | haley@h-squared.com.au |

**Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate, "expect," "intend," "may," "plan," "predict," "project," "target, "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Placement, the expected gross proceeds from the Placement and the intended use of proceeds of the Placement, the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.